Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Highly Accessed Editorial

How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?

Nadine Norton and Edith A Perez*

Author Affiliations

Mayo Clinic, 4500 San Pablo Rd S., Jacksonville, FL 32224, USA

For all author emails, please log on.

Breast Cancer Research 2013, 15:101  doi:10.1186/bcr3335


See related research by Vaz-Luis et al., http://breast-cancer-research.com/content/14/5/R129

Published: 14 January 2013

Abstract

Clinical outcome of patients with breast cancer is based on patient and tumor-related factors. The relevant tumor-related factors include anatomical extent and biology. Of the prognostic and predictive biological markers available, hormone receptors (defined as estrogen and progesterone receptors) and HER2 receptors, have been independently validated. Pertinent questions to be addressed include their combined impact on prognosis, their relevance in terms of sites of metastases, and whether they change in primary versus recurrent tumors. Although these questions are being addressed in clinical trials, epidemiological results, such as those derived from the National Comprehensive Cancer Network dataset, add perspective to our understanding of these two most relevant biological prognostic/predictive markers.